Protein kinase C and lung carcinogenesis
Protein kinase C and lung carcinogenesis
批准号:
10733467
负责人:
David Feldser
金额:
$67.44万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-06-06 至 2028-05-31
关键词:
ActinsAdenocarcinoma CellAffectAnimalsBenzo(a)pyreneBiologyBiosensorCRISPR/Cas technologyCancer EtiologyCancer ModelCarcinogensCarcinomaCell SeparationCellsCellular biologyCessation of lifeClinicalClustered Regularly Interspaced Short Palindromic RepeatsCompetenceCytoskeletal ModelingDataDefectDevelopmentDimensionsDiseaseEnvironmental CarcinogensEpithelial CellsEpitheliumEventExposure toExtracellular MatrixFamilyFluorescenceFluorescence Resonance Energy TransferGene ExpressionGeneticGenetically Engineered MouseGoalsGrantGuanine Nucleotide Exchange FactorsGuanosine TriphosphateHematopoieticHumanIn VitroInvadedJointsKRAS oncogenesisKRAS2 geneKRASG12DKnock-outLinkLipidsLoxP-flanked alleleLungLung AdenocarcinomaLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMass Spectrum AnalysisMediatingMembraneMesenchymeModelingMolecularMonomeric GTP-Binding ProteinsMusMutationNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNude MiceOncogenicOutcomePatientsPeptide HydrolasesPhenotypePhorbol EstersPhosphorylationPhosphotransferasesPlayPositioning AttributeProductionProtein AnalysisProtein DeficiencyProtein Kinase CPublishingRAS driven cancerRationalizationReceptor Protein-Tyrosine KinasesRecurrenceRoleSecond Messenger SystemsSeriesSignal PathwaySignal TransductionStromal CellsTechniquesTestingTumor PromotersWorkadenomacancer cellcancer initiationcandidate identificationcell motilitycell typeexperiencein vivoinnovationinsightlung cancer celllung carcinogenesislung metastaticlung tumorigenesismalignant breast neoplasmmembermouse modelmutantneoplastic cellnovelpermissivenessprotein activationprotein kinase C epsilonprotein kinase C kinaserac1 GTP-Binding Proteinreceptorscreeningtargeted treatmenttumortumor initiationtumor microenvironmenttumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Lung cancer is the leading cause of cancer-related deaths in the U.S., with ~236,700 new cases and ~130,200
deaths estimated for 2022. A joint effort by both PIs in this grant led to the identification of the oncogenic kinase
protein kinase C epsilon (PKCe) as a key player in lung carcinogenesis. PKCe is aberrantly up-regulated in lung
adenocarcinoma and is associated with poor outcome in patients specifically harboring KRAS mutations. Using
genetically engineered mouse (GEM) models, we demonstrated that PKCe is required for both carcinogen- and
Kras-driven lung tumorigenesis. In addition to this role in cancer initiation, our work established novel roles for
PKCe in cellular events associated with late cancer stages. Indeed PKCe is a major player in lung cancer cell
motility and invasion via activation of the small G-protein Rac1, linking this kinase to metastatic dissemination. That
PKCe plays critical permissive roles first during adenoma initiation and then again later during the acquisition of
metastatic competency highlights the functional complexities of the PKCe signaling events in lung cancer.
Interestingly, CRISPR-mediated inactivation of PKCe in the initiating cell-of-origin does not significantly affect Kras-
G12D-induced tumor development, leading us to hypothesize that PKCe does not strictly act in a tumor cell
autonomous manner to permit oncogenic KRAS-mediated tumorigenesis. To test this hypothesis, in Aim 1 we will
generate and characterize a series of GEM models to restrict genetic deletion of PKCe to either oncogenic Kras-
expressing cancer cells or to diverse stromal cell types present in the tumor microenvironment, including non-
cancerous epithelial, mesenchyme and hematopoietic cells. Gene expression studies on isolated cells using
fluorescence-based lineage tracing techniques will provide significant mechanistic insights. In Aim 2, we will
thoroughly dissect the mechanistic basis of motility/invasive signaling activation by PKCe. Our hypothesis is that
PKCe activates Rac1-mediated formation of cell ruffles and motility in KRAS mutant lung cancer cells via Rac
Guanine nucleotide Exchange Factors (Rac-GEFs). We will identify and characterize candidate Rac-GEFs as
PKCe effectors responsible for this phenotype. In Aim 3, we will establish the involvement of PKCe and its effector
Rac-GEFs for the development of metastatic lung cancer. We will use combined in vitro and in vivo approaches to
pin down mechanistic defects in the metastatic cascade upon CRISPR-mediated deletion of PKCe and Rac-GEFs
in lung adenocarcinoma cells. We will establish GEM models and use lentiviral CRISPR-based approaches to
determine the permissive contribution of PKCe and its GEF effectors to lung adenocarcinoma metastasis, and
identify relevant gene expression and signaling signatures contributing to this phenotype. Thus, by using
innovative, state-of-the-art genetic and molecular approaches, our studies should reveal the vast multidimensional
complexity of PKCe signaling in lung cancer development as well as underscore unappreciated mechanisms of
carcinogen- and KRAS-mediated lung oncogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
-
批准号:10539347
-
项目类别:
-
资助金额:$43.91万
-
财政年份:2021
-
负责人:David Feldser
-
依托单位:
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
-
批准号:10366169
-
项目类别:
-
资助金额:$44.59万
-
财政年份:2021
-
负责人:David Feldser
-
依托单位:
Deconstructing the multi-faceted roles of Rb in tumor progression
-
批准号:9755390
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2018
-
负责人:David Feldser
-
依托单位:
Deconstructing the multi-faceted roles of Rb in tumor progression
-
批准号:10227061
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2018
-
负责人:David Feldser
-
依托单位:
Deconstructing the multi-faceted roles of Rb in tumor progression
-
批准号:10477470
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2018
-
负责人:David Feldser
-
依托单位:
p53-Mediated Tumor Immune Surveillance
-
批准号:8985286
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2015
-
负责人:David Feldser
-
依托单位:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
-
批准号:8616117
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2011
-
负责人:David Feldser
-
依托单位:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
-
批准号:8334638
-
项目类别:
-
资助金额:$11.66万
-
财政年份:2011
-
负责人:David Feldser
-
依托单位:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
-
批准号:8787676
-
项目类别:
-
资助金额:$23.68万
-
财政年份:2011
-
负责人:David Feldser
-
依托单位:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
-
批准号:8240326
-
项目类别:
-
资助金额:$11.66万
-
财政年份:2011
-
负责人:David Feldser
-
依托单位:
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression
-
批准号:8707313
-
项目类别:
-
资助金额:$23.62万
-
财政年份:2011
-
负责人:David Feldser
-
依托单位:
海外基金